Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| MEI Pharma Inc. | Eganelisib + pembrolizumab - (MARIO-8) | Squamous Cell Carcinoma of the Head and Neck (SSCHN) | Phase 2 | Ongoing | Intravenous | Oncology |
| MEI Pharma Inc. | Zandelisib - (MIRAGE) | Indolent B-cell Non-Hodgkin's Lymphoma (iB-NHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and Waldenström's macroglobulinemia (WM) | Phase 2 | Trial Discontinued | Oral | Oncology |
| MEI Pharma Inc. | Zandelisib with RITUXAN (rituximab) and VENCLEXTA (venetoclax) - (CORAL) | Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Trial Discontinued | Oral | Oncology |
| MEI Pharma Inc. | Voruciclib plus Venclexta (venetoclax) | B-Cell Malignancies or Acute Myeloid Leukemia (AML) | Phase 2 | Trial Planned | Oral | Oncology |
| MEI Pharma Inc. | Zandelisib (ME-401) - (TIDAL) | Relapsed/refractory Follicular Lymphoma (FL) Non Hodgkin Lymphoma | Phase 2 | Trial Discontinued | oral | Oncology |
| MEI Pharma Inc. | Pracinostat in combination with Vidaza | High-risk Myelodysplastic Syndrome (MDS) | Phase 2 | Trial Discontinued | Oral | Hematology |
| MeiraGTx Holdings plc | Botaretigene Sparoparvovec (bota-vec) - (LUMEOS) | X-Linked Retinitis Pigmentosa | Phase 3 | Enrollment Conclusion | Subretinal | Genetic Disorder |
| MeiraGTx Holdings plc | AAV-RPE65 | RPE65-Deficiency | Phase 3 | Ongoing | Subretinal | Genetic Disorder |
